After July 1, 2026, the company plans to no longer manufacture the G6, its previous-generation CGM. This marks a transition to the company’s latest-generation G7, and perhaps an eventual look ahead to future CGMs.
G6 has been on the market in the U.S. since its FDA clearance in March 2018.
The website notice reads:
“Please be informed that Dexcom will no longer manufacture the Dexcom G6 CGM System after July 1, 2026. While supplies may continue to be available through your local pharmacy or medical distributor for a period of time after that date, we cannot guarantee availability.”
San Diego-based Dexcom recommends that customers work with doctors to upgrade to either Dexcom G7 or G7 15 Day.
Read more about Dexcom and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Visit here to purchase our Medtech Market Special Report on CGMs.
A recent class action lawsuit brought G7 into the spotlight, demanding a jury trial for claims that Dexcom’s representations for G7 were false, misleading, and deceptive to consumers.
The lawsuit says G7 places users at risk of severe hypoglycemia, hyperglycemia, seizure, coma, or death due to its design. It also alleges that software defects caused inaccurate blood glucose readings and suppressed, delayed or failed alerts. Additionally, users claim the CGM failed to last the intended 10-day wear period as advertised at the time.
FDA recalls in June and September of this year are referenced in the lawsuit. The agency labeled both Class I, the most serious kind. These recalls came just months after the company faced an FDA warning letter as well.
On the company’s third-quarter earnings call, interim CEO (and CEO-designate in the new year) Jake Leach and EVP, CFO and Chief Accounting Officer Jereme Sylvain outlined the issues identified by G7 users and shared more information on Dexcom’s future.
The company also has a next-generation G8 platform under development, according to BTIG analysts. They said in June that G8 will feature a smaller form factor, improved accuracy and more built-in features, such as multi-analyte capabilities. There is no timeline on G8’s path to market at this time, though.
